Stocktoria
Lupin Limited LUPIN.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Lupin Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹274.9B | ₹221.9B | ₹196.6B | ₹162.7B |
| Gross profit | ₹201.6B | ₹153.5B | ₹125.1B | ₹90.1B |
| SG&A expense | — | ₹28.0B | ₹26.0B | ₹21.2B |
| Operating income | ₹146.8B | ₹41.1B | ₹28.0B | ₹8.9B |
| Interest expense | ₹4.3B | ₹2.9B | ₹2.8B | ₹2.4B |
| Income tax | ₹15.2B | ₹7.1B | ₹4.9B | ₹2.7B |
| Net income | ₹53.3B | ₹32.8B | ₹19.1B | ₹4.3B |
| EPS (diluted) | ₹116.44 | ₹71.69 | ₹41.87 | ₹9.41 |
| Operating cash flow | ₹73.3B | ₹30.0B | ₹36.5B | ₹19.0B |
| Free cash flow | ₹52.8B | ₹13.2B | ₹27.2B | ₹4.0B |
| Cash & equivalents | ₹41.7B | ₹19.3B | ₹11.9B | ₹12.8B |
| Inventory | ₹60.8B | ₹54.8B | ₹49.5B | ₹44.9B |
| Goodwill | ₹26.6B | ₹22.3B | ₹23.3B | ₹22.2B |
| Total assets | ₹383.6B | ₹292.0B | ₹240.0B | ₹229.6B |
| Total debt | ₹66.2B | ₹54.5B | ₹29.2B | ₹45.4B |
| Total liabilities | ₹158.5B | ₹119.1B | ₹96.2B | ₹104.1B |
| Shareholders' equity | ₹224.5B | ₹172.0B | ₹142.9B | ₹124.6B |
| Share buybacks | ₹670.7M | ₹0 | — | — |
Growth · year-over-year · Revenue CAGR 19.1%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +23.9% | +12.9% | +20.8% | — |
| Net income growth | +62.5% | +71.4% | +345.1% | — |
| EPS growth | +62.4% | +71.2% | +345.0% | — |
| Free cash flow growth | +300.7% | -51.6% | +583.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.